Severin Schwan

Chief Executive Officer, Roche Group

After completing his studies in economics and law at the University of Innsbruck in Austria, Severin, joined the Roche Group in 1993 as a trainee in corporate finance. Thirteen years later, he was appointed CEO of Roche’s Diagnostics Division, and in 2008 he became CEO of the Roche Group. The company’s cancer immunotherapy Tecentriq (atezolizumab), a PD-L1 inhibitor, this year became the first immunotherapy approved for breast cancer in the US.

Part of the Power List 2019

Breakthroughs at the bench, novel technologies and groundbreaking policies and regulation have helped the pharma industry grow from strength to strength. After months of collating reader nominations and judging overseen by a panel of industry experts, we proudly present The Medicine Maker 2019 Power List, featuring 100 of the industry’s pioneers across four categories: Industry Influencers, Business Captains, Masters of the Bench, and Champions of Change.

Go to The Power List 2019